Generator-produced alpha-emitters
References (24)
- et al.
At-211 Radiocolloid Therapy: Further Observations and Comparisons with Radiocolloids of P-32, Dy-165, and Y-90
International Journal of Radiation Oncology and Biological Physics
(1984) - et al.
Apply. Radiat. Isot.
(1994) - et al.
J. Inorg. Nucl. Chem.
(1967) - et al.
Cyclotron Isotopes and Radiopharmaceuticals, XXXV. Astatine-211
International Journal of Applied Radiation and Isotopes
(1985) - et al.
Excitation Function for the 209Bi(7Li, 5n)211Rn Nuclear Reaction
Int. J. Appl. Radiat. Isot.
(1980) - et al.
Production of As and Rn Isotopes by Photospallation of 232Th and 238U
Int. J. Appl. Radiat. Isot.
(1979) - et al.
Int. J. Nucl. Med. Biol.
(1982) - et al.
A Remote System for the Separation of 228Th and 224Ra
J. Radioanal. Nucl. Chem., Letter
(1987) - et al.
Optimizations of Radiolabeling of Immuno-proteins with 213Bi
- et al.
Radioimmuno-therapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac
Cancer Research
(1994)
Effective alpha-particle-mediated radioimmunotherapy of murine leukemia
Cancer Res.
Pharmacokinetics and Bioactivity of DOTA-Bismuth Conjugated Anti-Tac Antibody for Alpha Emitter Therapy
Cancer Research
Cited by (57)
Radionuclide generators
2022, Nuclear Medicine and Molecular Imaging: Volume 1-4Production, purification and availability of <sup>211</sup>At: Near term steps towards global access
2021, Nuclear Medicine and BiologyCitation Excerpt :A 211Rn/211At generator allows 211At to grow in and reach its maximum radioactivity level at 14.5 h. Moreover, over 80% of the maximum 211At activity level is still available on the generator after 24 h. This permits delivery of a generator to remote locations while 211At grows in during transportation, extending the time period for efficient 211At distribution significantly [80,81]. Radon-211 can be produced via multiple nuclear reactions; however, the most relevant approaches are the bombardment of natural bismuth targets with 42-MeV 6Li ions via the 209Bi(6Li,4n)211Rn reaction [82], or with 60-MeV 7Li beams via the 209Bi(7Li,5n)211Rn reaction [83].
Innovation, Impact, and Strategic Importance of Alpha-Emitting Radionuclides
2019, Journal of Medical Imaging and Radiation SciencesCitation Excerpt :The following year, I managed to secure some funding to get access to the rest of the sludge in the waste tanks, and the 229Th recovered from this waste material constitutes the bulk of ORNL Stock. In the next ten years, from 1996 to 2005, numerous publications by Boll et al [17–19], Sitnikov and Khalkin et al [20,21], Apostolidis et al [22], McDevitt et al [28,29], Kennel et al [30,31], Davis et al [32], and Mirzadeh [26] describe methods for extraction and purification of 229Th stock material and extraction of 225Ac from 225Ra and 229Th, the construction of 225Ac/213Bi generator system and preclinical studies. The climax of these early efforts was publication of an article entitled “Tumor therapy with targeted atomic nanogenerators” by McDevitt et al in Science in 2002 [33] and the results of first clinical trial for the treatment of myeloid leukemia with 213Bi labeled HuM195 antibody by Jurcic et al in the same year [34].
The Performance of two silica based ion exchange resins in the separation of <sup>213</sup>Bi from its parent solution of <sup>225</sup>Ac
2018, Applied Radiation and IsotopesCitation Excerpt :The 213Bi tagged peptide DOTATOC induced remission in neuroendocrine tumors with moderate kidney toxicity (Kratochwil et al., 2014). 213Bi is the daughter of 225Ac and decays by way of an 8.4 MeV alpha particle (Mirzadeh, 1998). Studies show that 225Ac can be used as a generator to produce 213Bi with an ion exchange resin used to separate the 213Bi from the 225Ac (Guseva and Dogadkin, 2009; McDevitt et al., 1999a, 1999b; Mirzadeh et al., 1998; Morgenstern et al., 2012).
<sup>211</sup>Rn/<sup>211</sup>At and <sup>209</sup>At production with intense mass separated Fr ion beams for preclinical <sup>211</sup>At-based α-therapy research
2017, Applied Radiation and IsotopesCitation Excerpt :Moreover, the short distribution range of 211At from its site of production to potential researchers and hospitals is constrained by its short 7.21 hour half-life. While not equipped with a medium energy α-particle accelerator, as is conventionally used to produce 211At, TRIUMF has made advances toward the availability of 211At by pursuing its production through radon-211 (211Rn, t1/2 = 14.6 hours) electron capture (e.c.) decay (73% per 211Rn decay), a strategy referred to as the 211Rn/211At generator system (Meyer and Lambrecht, 1981; Mirzadeh and Lambrecht, 1987, Mirzadeh, 1998). Since the 211At is continually produced from a decaying supply of 211Rn, the highest yields for 211At are recoverable from this generator system up to one day after the initial 211Rn production and isolation.